Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduodenectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution
Open Access
- 15 April 2017
- journal article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 49 (2), 473-483
- https://doi.org/10.4143/crt.2016.166
Abstract
This study was conducted to evaluate the long-term outcome in patients undergoing pancreaticoduodenectomy (PD) followed by adjuvant chemoradiotherapy for distal cholangiocarcinoma (DCC) in a high-volume center and to identify the prognostic impact of clinicopathologic factors. A total of 132 consecutive patients who met the inclusion criteria were retrieved from the institutional database from January 1995 to September 2009. All patients received adjuvant treatments at a median of 45 days after the surgery. Median follow-up duration was 57 months (range, 6 to 225 months) for all patients and 105 months for survivors (range, 13 to 225 months). The 5-year locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) rates were 70.7%, 55.7%, 49.4%, and 48.1%, respectively. Univariate analysis revealed poorly differentiated (P/D) tumors and lymph node (LN) metastasis were significantly associated with DMFS and OS. Additionally, preoperative carbohydrate antigen 19-9 level was significantly correlated with DFS, LRRFS, and DMFS. Upon multivariate analysis for OS, P/D tumors (p=0.015) and LN metastasis (p=0.003) were significant prognosticators that predicted inferior OS. Grade 3 or higher late gastrointestinal toxicity occurred in only one patient (0.8%). Adjuvant chemoradiotherapy after PD for DCC is an effective and tolerable strategy without significant side effects. During long-term follow-up, we found that prognosis of DCC was mainly influenced by histologic differentiation and LN metastasis. For patients with these risk factors, further research should focus on improving adjuvant strategies as well as other treatment approaches.Keywords
Funding Information
- Armed Forces Medical Research Institute (2015-AFMRI-02)
- Ewha Womans University
This publication has 29 references indexed in Scilit:
- Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013Cancer Research and Treatment, 2016
- Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results, prognostic factors, and long-term follow-upLangenbecks Archives Of Surgery, 2015
- Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases.2014
- The prognostic factors for survival after curative resection of distal cholangiocarcinoma: perineural invasion and lymphovascular invasionSurgery Today, 2014
- Patterns of failure and prognostic factors in resected extrahepatic bile duct cancer: implication for adjuvant radiotherapyRadiation Oncology Journal, 2014
- Impact of intrapancreatic or extrapancreatic bile duct involvement on survival following pancreatoduodenectomy for common bile duct cancerBritish Journal of Surgery, 2013
- Distant Metastasis Risk Stratification for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiation for Extrahepatic Bile Duct CancerInternational Journal of Radiation Oncology*Biology*Physics, 2012
- Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinomaAnnals Of Oncology, 2012
- Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in JapanJournal of Hepato-Biliary-Pancreatic Surgery, 2008
- CholangiocarcinomaAnnals of Surgery, 1996